Expert consensus on the burden of respiratory syncytial virus disease and the utility of nirsevimab for disease prevention and protection of infants.

ABSTRACT:

Background

Respiratory syncytial virus (RSV) is the most common cause of pediatric acute lower respiratory tract infection worldwide. In Singapore, RSV substantially contributes to the morbidity and mortality of children aged < 5 years, particularly during their first year of life, with hospitalization rates peaking during epidemic outbreaks. This expert consensus paper aims to provide an overview of the RSV disease burden, unmet needs, and the urgency for RSV prevention in all infants.

Data sources

A comprehensive literature review was conducted using Medline via PubMed, to identify relevant studies, including randomized controlled trials, observational studies, systematic reviews, and meta-analyses, related to RSV burden and prevention and nirsevimab. A multidisciplinary g

SUBMITTER: Goh DYT 

PROVIDER: S-EPMC12627213 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature